(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.40%) $2 337.70
(1.00%) $27.53
(0.68%) $928.40
(-0.16%) $0.933
(-0.12%) $11.01
(-0.22%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.47%
@ $8.24
発行日: 15 2月 2024 @ 05:41
リターン: -36.13%
前回のシグナル: 2月 14 - 05:50
前回のシグナル:
リターン: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
本日の出来高 | 1.22M |
平均出来高 | 1.21M |
時価総額 | 400.28M |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00800 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
INSIDER POWER |
---|
89.25 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 106 721 |
ボリューム 相関
Travere Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Travere Therapeutics, 相関 - 通貨/商品
Travere Therapeutics, 財務諸表
Annual | 2023 |
収益: | $145.24M |
総利益: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2023 |
収益: | $145.24M |
総利益: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2022 |
収益: | $212.02M |
総利益: | $204.43M (96.42 %) |
EPS: | $-4.37 |
FY | 2021 |
収益: | $227.49M |
総利益: | $220.71M (97.02 %) |
EPS: | $-3.79 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。